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Abstract 
Background: There is a need to establish the effectiveness, cost-effectiveness and safety of allergen 
immunotherapy (AIT) for the prevention of allergic disease. 
Methods: Two reviewers independently screened nine international biomedical databases. Studies were 
quantitatively synthesized using random-effects meta-analyses. 
Results: 32 studies satisfied the inclusion criteria. Overall, meta-analysis found no conclusive evidence 
that AIT reduced the risk of developing a first allergic disease over the short-term (RR=0.30; 95%CI 0.04 
to 2.09) and no randomized controlled evidence was found in relation to its longer-term effects for this 
outcome. There was however a reduction in the short-term risk of those with allergic rhinitis developing 
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asthma (RR=0.40; 95%CI 0.29 to 0.54), with this finding being robust to a pre-specified sensitivity 
analysis. We found inconclusive evidence that this benefit was maintained over the longer-term: RR=0.62; 
95%CI 0.31 to 1.23. There was evidence that the risk of new sensitization was reduced over the short-
term, but this was not confirmed in the sensitivity analysis: RR=0.72; 95%CI 0.24 to 2.18.  There was no 
clear evidence of any longer-term reduction in the risk of sensitization: RR=0.47; 95%CI 0.08 to 2.77. 
AIT appeared to have an acceptable side-effect profile.  
Conclusions: AIT did not result in a statistically significant reduction in the risk of developing a first 
allergic disease. There was however evidence of a reduced short-term risk of developing asthma in those 
with allergic rhinitis, but it is unclear whether this benefit was maintained over the longer-term.  We are 
unable to comment on the cost-effectiveness of AIT. 
 
Keywords: allergen immunotherapy, allergic diseases, allergy, atopy, prevention, sensitization. 
 
BACKGROUND 
 
Over recent decades, allergen immunotherapy (AIT) has been investigated and used for the treatment of 
allergic rhinitis (AR)/rhinoconjunctivitis, asthma and venom allergy. AR and asthma often co-exist and up 
to 50% of patients with AR have bronchial hyperreactivity(BHR)(1). Children with AR have over three 
times greater risk of developing asthma later on in life when compared to those without AR(2), especially 
those with BHR(3). Studies assessing the long-term effectiveness of AIT–especially in those with AR–
suggest that AIT might reduce the risk of developing asthma(4;5).  AIT may also result in a reduced risk 
for development of new allergic sensitization(s) suggesting a possible mechanism through which this 
protection is conferred(6;7;8). As a consequence, interest has broadened from a sole focus on the 
therapeutic effects of AIT treatment to one that also includes investigation of the potential preventive 
effects of AIT. 
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Several populations might benefit from the preventive effects of AIT. Firstly, in healthy individuals, with 
or without IgE-sensitization, AIT might prevent the development of allergic diseases. Secondly, in 
individuals with allergic manifestations at any stage,  AIT may prevent the development of other allergic 
conditions such as the development of asthma in those with AR. Finally, AIT may prevent the 
development of addiitonal sensitization in patients who are already sensitized, as well as the spreading of 
allergic sensitization at the molecular level.  
 
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing 
Guidelines for AIT. This systematic review is one of five inter-linked evidence syntheses conducted in 
order to provide a state-of-the-art synopsis of the current evidence base in relation to evaluating AIT for 
the treatment of AR, food allergy, venom allergy, allergic asthma and its role in allergy prevention. The 
focus of this review is on assessing the preventive capacity of AIT. The information derived from this 
systematic review will help to inform  key clinical recommendations and the identification of future 
research needs. The potential effect of early introduction of different food allergens into the diet of 
infants will not be addressed in this review, since it will be covered by the planned update of the 
prevention part of the EAACI Food Allergy and Anaphylaxis Guidelines. 
 
AIMS 
We sought to assess the effectiveness, cost-effectiveness and safety of AIT for the prevention of allergic 
disease and allergic sensitization.  
 
METHODS 
Details of the methodology used for this review, including search terms and filters; databases searched; 
inclusion and exclusion criteria; data extraction and quality appraisal have been previously reported(9). We 
therefore confine ourselves here to a synopsis of the methods employed. 
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Inclusion criteria 
Patient characteristics 
We were interested in studies on subjects of any age with or without allergic sensitization(s) and subjects 
with or without allergic disease.  
 
Interventions and comparators 
We were interested in AIT administered through any route (e.g. subcutaneous (SCIT), sublingual (SLIT)) 
compared with no intervention, placebo or any active comparator using different allergens (e.g. pollens, 
house dust mites (HDM)), including modified allergens.  
 
Outcomes 
Primary outcomes 
The primary outcomes of interest were the development of first allergic disease or of a new allergic 
disease, in those with a previous allergic condition, assessed over the short-term (i.e. <2 years of 
completion of AIT) and longer-term (i.e. ≥2 years post-completion of AIT) using well defined diagnostic 
criteria.  
 
Secondary outcomes 
Secondary outcomes were: the development of: new allergic sensitization(s) (or allergic 
immunresponse(s)); spreading of allergic sensitization(s) from one allergen to other non-related 
allergen(s); spreading of allergic sensitization(s) at molecular level, from one allergenic molecule to other 
molecules; development of new oral allergy syndrome (OAS); health economic analyses from the 
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perspective of the health system/payer; and safety as assessed by local and systemic reactions in 
accordance with the World Allergy Organization’s (WAO) grading system of side-effects(10;11).  
 
Study design 
We were interested in systematic reviews, randomized controlled trials (RCTs), quasi-experimental 
studies, health economic analyses, and large case series with a minimum of 300 patients. 
 
Search strategy 
Our search strategy was conceptualized to incorporate the four elements shown in Figure 1 (Appendix 1). 
Additional unpublished work and research in progress was identified through discussion with experts in 
the field (Appendix 2). No language restrictions were employed.  
 
Quality assessment 
Quality assessment was conducted using established tools as detailed in the protocol(9). Assessments were 
independently carried out on each study by two reviewers. Any discrepancies were resolved by discussion 
or, if agreement could not be reached, by arbitration by the third reviewer. 
 
Data analysis and synthesis  
Data were independently extracted onto a customized data extraction sheet in DistillerSR by two 
reviewers, and any discrepancies were resolved by discussion or, if agreement could not be reached, by 
arbitration by a third reviewer.  
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A descriptive summary with data tables was produced to summarize the literature. Where possible and 
appropriate, meta-analysis was undertaken using random-effects meta-analyses using Stata (version 14).  
   
Sensitivity and subgroup analyses, and assessment for publication bias 
Sensitivity analyses were undertaken by comparing the summary estimates obtained by excluding studies 
judged to be at high risk of bias with those judged to be at low or moderate risk of bias.   
 
Subgroup analyses were undertaken to compare: 
 Children versus adults 
 Route of administration 
 Allergens used for AIT. 
 
We were unable to assess publication bias through the creation of funnel plots due to the small number 
of studies, but were able to use Eggar’s test(12). 
 
Registration and reporting of this systematic review 
This systematic review is registered with PROSPERO with registration number: CRD42016035380 . It is 
reported in accordance with the PRISMA guidelines (Appendix 3).  
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RESULTS 
Overview of studies 
We identified a total of 10,704 potentially eligible studies after removal of duplicates. Of these, 32 studies 
reported in 34 publications and one entry into an online trial repository fulfilled the inclusion criteria 
(Figure 2)(3;6-8;13-43).  
 
In terms of study design, 17 RCTs and 15 controlled-before-after (CBA) studies were identified. The key 
characteristics and main findings of the RCTs can be found in Table 1 and for the CBAs in Table 2. 
Nineteen studies included children; eight studies enrolled adults only; and five studies included both child 
and adult subjects. The numbers of subjects included in these studies varied from 28-691 for the majority 
(N=30) of studies. However, two CBAs reported on substantially larger populations: 8,396 subjects(7), 
and  118,754 subjects(16), respectively.   
 
The allergens in the AIT studied were HDM, peach, pollen from grass, birch, ragweed, Japanese cedar or 
Parietaria Judaica, Cladosporium herbarum, Penicillium notatum, Aspergillus fumigatus, Alternaria alternata, Mucor 
racemosus, Quercus alba, Cynodon dactylon, Ambrosia elatior, Plantago lanceolata, Phleum pratense/Dactylis 
glomerata/Lolium perenne (PDL) grass mix, Dermatophagoides pteronyssinus and Dermatophagoides farinae, either as 
single allergens or as multiple allergens. Peach was the only food allergen included in the identified AIT 
studies. The routes of administration were SCIT, oral and SLIT in the form of tablets and drops.  
 
The overall quality of the identified RCTs varied with five RCTs judged to be at low risk of 
bias(8;14;19;31;42) six at medium risk(13;18;23;24;35;40) and six at high risk of bias(3;17;22;25;28;37). All 
CBAs were judged to be at high risk of bias (Tables 3 and 4).  
Our main findings are presented according to primary and secondary outcomes of the review. 
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Primary outcomes: development of new allergic disease 
We identified 12 studies reported in a total of 14 publications and an entry into an online trial repository 
on the effectiveness of AIT for the prevention of development of new allergic disease in previously 
healthy subjects or in subjects already suffering from one or more allergic disease(3;8;13;15-25). All except 
the study by Schmitt(16) were RCTs. The Preventive Allergy Treatment (PAT) study reported two 
updates from the same trial (i.e. three reports in total)(3;20;21).  
 
Three RCTs investigated the preventive effects of AIT in relation to development of the first allergic 
disease in healthy asymptomatic individuals. They focused on the effect of SLIT on cedar pollinosis(25), 
eczema, wheeze and food allergy(8), and asthma(13), respectively.  
 
The majority of studies (N=8) focused on the preventive effect of AIT in relation to the development of 
asthma in patients with established AR(3;14;15;17-24). SCIT was used in four of these RCTs (3;17-21) 
whilst SLIT through drops or tablets were used in four RCTs(14;15;22-24). In the CBA study using 
routine healthcare data, patients were stratified according to mode of administration (i.e. SCIT, SLIT 
drops, SLIT tablets, and combinations of SCIT and SLIT)(16).  
 
Short-term preventive effects of AIT 
The short-term preventive effect of AIT was investigated in two RCTs judged to be at low risk of 
bias(8;19), three RCTs at medium risk of bias(18;23;24), two RCTs at high risk of bias(22;25), and one 
CBA at high risk of bias(16).  
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In terms of mode of administration, SCIT was used in two RCTs(18;19), oral (drops or capsules) (8;23) 
and SLIT (tablets and drops) in the remaining three RCTs(8;23;24). In the CBA, SCIT, SLIT drops and 
SLIT tablets were administered(16).  
 
RCTs on short-term preventive effects 
Prevention of the onset of first allergic disease 
The potential effects of oral AIT for the primary prevention of atopic eczema, wheeze, food allergy and 
sensitizations were investigated in a recent RCT at low risk of bias by Zolkipli.(8) Infants at high risk of 
atopy based on family history of allergic diseases were randomized to receive either oral HDM AIT 
(drops) or placebo twice daily for a year. Upon completion of the trial, no significant difference was seen 
between the active or placebo groups in the risk of developing eczema (P=0.20), wheeze (P=0.40) or 
food allergy (P=0.26) in these children(8). 
 
A second RCT by Yamanaka, at high risk of bias, looked at primary prevention in asymptomatic adults 
sensitised to Japanese cedar pollen. They were randomized to SLIT or placebo and in the second year 
none of the active group had developed pollinosis compared to seven in the placebo group 
(P=0.0098)(25). 
 
Meta-analysis of data from these two trials showed no overall reduction in the risk of developing a first 
allergic disease: RR=0.30 (95%CI 0.04 to 2.09) (Figure 3). Sensitivity analysis excluding Yamanaka did not 
alter this conclusion. 
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Prevention of onset of asthma in those with established AR 
An RCT at low risk of bias by Grembiale, investigating the preventive effects of SCIT administered for a 
two-year period to subjects with AR,  found no significant differences in asthma prevalence at the end of 
the trial among the AIT group compared to controls (P=0.49)(19).  
 
The RCT at medium risk of bias by Crimi investigated the effect of SCIT  for three years on the 
development of asthma and BHR among 30 non-asthmatic adults with seasonal AR who were mono-
sensitized to Parietaria judaica(18). No significant differences in preventive effect were identified across 
intervention and control group. At the end of the trial, 47% of patients in the placebo group (7/15) had 
developed asthma compared to 14% (2/14) in the SCIT group (P=0.056)(18).  
 
The RCT by Moller, at medium risk of bias, randomized 30 children with AR to birch pollen to AIT 
capsules or placebo(23). They found no cases of asthma at the end of the 10-month treatment period in 
the AIT group and five cases out of 16 in the control group (P-value not given).  
 
The large RCT by Novembre, at medium risk of bias, randomized 113 children, aged 5-14 with hay fever 
to grass pollen to SLIT drops co-seasonally for three years or conventional pharmacotherapy(24).  At the 
end of the three year trial, the relative risk of developing asthma was 3.8 (95%CI 1.5 to 10.0; P=0.041) in 
control subjects compared to the SLIT group(24).  
 
In the RCT by Marogna,  at high risk of bias, 216 children with AR and intermittent asthma were 
randomized to SLIT or conventional pharmacotherapy for a period of three years. They found a lower 
occurrence of  asthma in the SLIT group (30/66, 45.4%) compared with the control group (OR=0.04; 
95%CI 0.01 to 0.17)(22).  
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Random effects meta-analysis of these five RCTs plus the short-term effects of the first publication from 
the PAT trial (20) demonstrated a significant reduction in the risk of developing asthma: RR=0.40 
(95%CI 0.29 to 0.54) (Figure 4). There was no evidence of publication bias (P=0.27). This result remained 
significant after excluding the trial by Marogna and Moller (2002), which were both judged to be at high 
risk of bias: RR=0.38 (95%CI 0.20 to 0.72). Subgroup analyses showed that AIT was beneficial in those:  
 aged <18 (RR=0.40; 95%CI 0.26 to 0.61), but not in those aged ≥18 years (RR=0.28; 
95%CI 0.07 to 1.15) 
 receiving SLIT (RR=0.33; 95%CI 0.21 to 0.50) and those receiving SCIT (RR=0.49; 
95%CI 0.32 to 0.77) 
 receiving pollen AIT (RR=0.48; 95%CI 0.33 to 0.71), but not those receiving HDM AIT 
(RR=0.20; 95%CI 0.01 to 3.94).  
 
CBAs on short-term preventive effects 
Prevention of the onset of first allergic disease 
We found no relevant studies. 
Prevention of onset of asthma in those with established AR 
Only one CBA investigated the preventive effects of AIT(16). The study by Schmitt looked at 118,754 
patients with AR, but with no comorbid asthma, between 2007-12. Patients were stratified according to 
exposure to AIT in 2006 and followed to assess incident asthma. The authors reported a preventive effect 
of AIT on the progression from AR to asthma in patients exposed to AIT through any mode of 
administration (RR=0.60; 95%CI 0.42 to 0.84; P=0.003) compared to unexposed patients. When 
subdivided according to route of administration, there was a significant preventive effect of SCIT 
(RR=0.57; 95%CI 0.38 to 0.84; P=0.005) whereas effects of SLIT drops and combinations of SCIT and 
SLIT did not reach statistical significance(16). 
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Long-term preventive effects of AIT 
There were four RCTs, one judged to be at low risk(15), one to be medium risk(13) and two assessed to 
be of high risk of bias(3;17) investigating the longer-term preventive effects of AIT.  
 
RCTs on long-term preventive effects 
Prevention of onset of first allergic disease 
We found no relevant studies. 
 
Prevention of onset of asthma in those with established atopic dermatitis or AR 
An RCT at medium risk of bias explored the effect of 12 months of daily SLIT  on prevention of asthma 
and new sensitizations in children with atopic dermatitis and sensitization to one or more food 
allergens(13). As no differences in antibody levels between the SLIT and the placebo group could be 
identified six months into the trial, recruitment was terminated and the trial reduced to pilot study status. 
After 48 months of follow-up, there were no differences in asthma prevalence between the two 
groups(13). 
 
A large yet unpublished trial at low risk of bias explored the effect of SLIT tablets on the prevention of 
asthma in 812 children with grass pollen allergic rhinoconjuctivitis. Based on data available in EudraCT, 
the trial, undertaken in mono-sensitized children carried out over a five year period with three years of 
treatment and two years of follow-up study, failed to demonstrate the preventive effect of AIT on the 
development of asthma (OR=0.9; (95%CI 0.57 to 1.43)(14;15).   
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A third RCT by Jacobsen, at high risk of bias, explored the preventive effects of SCIT in relation to onset 
of asthma over a 10-year follow-up period(3;20;21). This trial enrolled 205 children with seasonal AR at 
baseline who were randomized to a three-year course of SCIT or no intervention. At 10-years  follow-up, 
the adjusted treatment effect showed a significantly higher OR of not having asthma of 4.6 (95%CI 1.5 to 
13.7) among subjects treated with SCIT compared to controls.  
 
The RCT by Song, at high risk of bias, looked at patients with AR, allergic to HDM, two years after 
discontinuation of three years of SCIT compared to standard pharmacotherapy. They found that no 
(0/51) patients in the SCIT group developed asthma compared to 9/51 in the control group (P-value not 
given)(17). 
 
Meta-analysis showed no overall evidence of reduction in the long term risk of developing asthma: 
RR=0.62; (95%CI 0.31 to 1.23) (Figure 5).   
 
Secondary outcomes 
We were planning to assess a range of six different secondary outcomes according to the protocol(9). 
However, we did not find studies related to spreading of allergic sensitization(s) at the molecular level, 
nor did we identify studies exploring development of new OAS after the end of the intervention or health 
economic analyses of AIT used for prevention.  
 
In the sections below, findings related to development of new allergic sensitization(s) and safety will be 
described. 
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Development of new allergic sensitization 
We found  23 studies investigating the effect of AIT on the development of new allergic sensitizations  
(6-8;17;22;26-43) including one trial reported in two publications(29;30). Nine studies were RCTs 
(8;17;22;28;31;35;36;40;42) and three of these(8;31;42) were assessed to be at low risk of bias. The 
remaining studies were all CBAs assessed to be at a high risk of bias. Of these, 12 (six RCTs and six 
CBAs) provided data on short-term effects and 11 (three RCTs and eight CBAs) provided data on long-
term effects. 
 
Short-term preventive effects 
RCTs  
There were six RCTs investigating this outcome. Three low risk of bias RCTs investigated the short-term 
effects of AIT on the risk of developing new sensitizations (8;31;42). The remaining three RCTs were  
moderate(40) or high risk of bias(22;36). 
 
The Zolkipli HDM oral AIT trial among infants at high risk of developing allergic disease found a 
significant reduction in sensitization to any common allergen in the active group compared to the placebo 
group (P=0.03) at the end of the trial, but no difference in HDM sensitization between the AIT (5.7%) 
and control groups (7.8%): risk difference: 2.2%; 95%CI -7.5 to 11.8; P=0.61(8).  
 
Garcia studied adult patients allergic to peach,  and found no relevant new sensitizations in the placebo 
group (n=17) and three new sensitizations to single allergens among the 37 patients in the SLIT group 
after six months of treatment; the AIT was therefore judged to be ineffective(31).  
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The RCT by Szépfalusi looked at the preventive effect of SLIT with grass pollen or HDM extract in 
mono-sensitized children aged 2-5 years; they found no difference in the rate of new sensitizations to 
HDM between groups after 12 and 24 months of SLIT(42).  
 
Three additional RCTs investigating the short-term effects of AIT, of  medium to high risk of bias, found 
significantly lower incidence of new sensitizations among children and adults with AR. The first, 
Marogna, found that in the group treated with SLIT for three years, 4/130 developed new sensitizations 
compared to the controls in whom 23/66 developed new sensitisations (OR=0.06; 95%CI 0.02 to 0.17). 
They further concluded that the SLIT group was less likely to be polysensitized compared to the SLIT 
group at year 3: OR=0.33 (95%CI 0.17 to 0.61)(22).  A second RCT conducted by Marogna found a 
significantly lower incidence of new sensitizations among the SLIT group compared to controls(36). At 
the end of the three-year treatment period, 16/271 (5.9%) in the SLIT group had developed new 
sensitizations compared to 64/170 (38%) among controls (P<0.001). The third RCT by Pifferi looked at 
children with asthma monosensitized to HDM treated with SCIT for three years compared to 
controls(40). At the end of treatment, they found no new sensitizations in the SCIT group (0/15) 
compared to 5/14 in the control group (P=0.01). 
 
Meta-analysis showed an overall reduction in the risk of allergic sensitization: RR=0.33 (95%CI 0.12 to 
0.93) (Figure 6). The Eggar test showed no evidence of publication bias (P=0.60).  Sensitivity analyses 
excluding the two studies by Marogna, at high risk of bias, however failed to confirm this risk reduction: 
RR=0.72; 95% CI 0.24 to 2.18.  
 
Subgroup analyses lacked precision, but suggested that AIT was: 
 likely to be beneficial in those aged <18 (RR=0.32; 95% CI 0.08 to 1.28), but not in 
those aged ≥18 years (RR=3.32; 95%CI 0.18 to 60.85) 
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 more likely to be beneficial in those receiving ≥3 years therapy (RR=0.13; 95%CI 0.08 to 
0.21) than in those receiving <3 years therapy (RR=0.74; 95%CI 0.13 to 4.21) 
 more likely to be beneficial in those receiving SCIT (RR=0.09; 95%CI 0.01 to 1.41) than 
SLIT (RR=0.38; 95%CI 0.13 to 1.13) 
 likely to be beneficial in those receiving HDM (RR=0.33; 95%CI 0.09 to 1.20), but not in 
those receiving peach (RR=3.32; 95%CI 0.18 to 60.85).  
 
CBAs  
The inconsistent evidence found in RCTs was also reflected in the included CBAs with four studies 
finding a lower occurrence of new sensitizations among AIT exposed subjects compared to unexposed 
subjects(6;34;38;41), one study reporting higher occurrence in the AIT group compared to controls(26), 
and three studies reporting no differences between groups (Table 2)(33;38;43).  
 
Long term preventive effects of AIT on the development of new allergic sensitization 
RCTs  
Three RCTs investigated the preventive long term (i.e. post-intervention) effects of AIT on onset of new 
sensitizations(17;28;35).   
 
The Limb RCT, at medium risk of bias, explored the effect of SCIT for 24 months with a mixture of up 
to seven aero-allergens among children with moderate-to-severe asthma recruited between 5-12 years of 
age and followed into adulthood(35). The mean follow-up time of the 82 subjects was 10.8 years. There 
was a similar development of new sensitivities among both the SCIT and placebo groups (P=0.13), and 
the types of new sensitivities were also found to be similar across groups(35).  
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The high risk of bias RCT conducted by Dominicus followed adult patients with allergic 
rhinoconjuncitivitis three years after cessation of SCIT for grass pollen and found that the number of 
subjects who did not develop new sensitizations were higher in the group exposed to SCIT (20/26; 77%) 
compared to the placebo group (3/13; 23%; P-value not given) (28).  
 
In an RCT at high risk of bias, Song followed patients with AR two years after cessation of SCIT for 
HDMs compared to patients receiving pharmacotherapy only(17). In the SCIT group, the occurrence of 
new sensitizations was 2/43 (4.7%) compared to 17/41 (41.5%) among controls (P<0.01). 
 
Meta-analyses of these studies showed no evidence of a reduction in the long-term risk of allergic 
sensitization: RR=0.47 (95%CI 0.08 to 2.77) (Figure 7). The Eggar test showed no evidence of 
publication bias (P=0.23) 
 
CBAs  
Among the seven CBAs investigating long-term preventive effects of AIT, one SLIT study by Di Rienzo 
found no significant differences in onset of new sensitizations among intervention and control groups 
during the 10 years of follow-up(27). Five studies, four SCIT and one SLIT, found reduced onset of new 
sensitizations among subjects exposed to AIT(7;29;34;37;39).    
 
In contrast to these findings, a SCIT CBA by Gulen found a significantly higher occurrence of new 
sensitization among children with asthma who were monosensitized to HDM exposed to AIT compared 
to controls(32).  
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Cost-effectiveness 
We found no studies investigating the cost-effectiveness of AIT for the prevention of allergy. 
 
Safety 
We identified a total of seven studies, six SLIT (five of these RCTs and one CBA), and one SCIT RCT, 
that reported on adverse events(8;15;22;36;37;40;42).  
 
In the SLIT studies, an RCT  at low risk of bias investigating effects of SLIT administered as drops to 
infants reported no differences in numbers or type of adverse reactions between intervention and control 
groups (8),  and a further RCT with low risk of bias among children between 2-5 years of age also 
reported no relevant side effects in 21,170 single applications(42). The incidence of generalized itching 
was reported in three SLIT studies assessed to be at high risk of bias: one RCT finding that 4/271 (1.5%) 
of the children exposed to SLIT experienced one episode of generalized itching that resolved without 
therapy(36), another RCT reported one incidence of systemic itching after SLIT among 144 children in 
the SLIT group(22), and a CBA reported that 5/57 adult patients exposed to SLIT had transient oral 
itching(37). In an RCT, assessed to be at medium risk of bias, the safety of SCIT was assessed among 
children aged 6-14 years(40). It reported no major local or systemic effects of AIT during three years of 
treatment among the 15 patients randomized to SCIT(40).  
 
DISCUSSION 
Statement of principal findings 
We found no consistent evidence from the limited body of RCT evidence that AIT can prevent the first 
onset of allergic disease over the short-term  and no RCTs investigating the long-term preventive effects 
of AIT. We did however find clear evidence of a substantial reduced risk of developing asthma in those 
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with pre-existing AR over the short-term, although it is unclear if this benefit was maintained over the 
longer-term. There was some evidence to indicate that the risk of allergic sensitization can be reduced 
over the short-term, but this was not confirmed in the pre-specified sensitivity analysis. There was no 
evidence of a long-term reduction in the risk of allergic sensitization. These risks were however in many 
cases imprecisely estimated and so need to be interpreted with caution.  Overall, the safety profile of AIT 
appeared acceptable, but we found no data on cost-effectiveness considerations and so are unable to 
comment on this outcome.   
 
Strengths and limitations 
The strengths of this study include the comprehensive literature search that was undertaken and 
adherence to a pre-published protocol with clearly defined objectives and a detailed pre-specified analysis 
plan. The main limitations relate to the possibility of not uncovering the total body of evidence on this 
subject and the challenges of interpreting a heterogeneous body of relatively small-scale trial evidence.   
 
Implications for policy, practice and research 
This review has highlighted the inconsistent evidence-base and the lack of robust evidence, in particular 
for long-term preventive effects of AIT and in terms of detailed subgroup analysis, which impedes our 
ability to tease out clear implications for healthcare policy and clinical practice. In terms of research, there 
is a need for high quality well powered RCTs with long-term follow-up and well defined diagnostic 
criteria to answer the above research questions. Furthermore, there is a need for studies with more robust 
assessment of adherence to AIT to ascertain the dose received and take into consideration the effect of 
non-adherence to treatment on preventive effectiveness. Future studies should also include possible effect 
modification caused by measures taken to alter behaviours and/or environmental triggers of allergy (e.g. 
exposure to passive smoking in childhood, presence of pets) as this may modify the effect of AIT on 
onset of allergy.  
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Conclusions  
This systematic review found only limited evidence to support the use of AIT in a preventive capacity. 
Based on the current evidence, we are unable to conclude that AIT prevents the development of first 
allergic disease. There appears to be short-term benefit in preventing asthma in those with AR, 
particularly if AIT is started in childhood with this benefit being seen for SCIT and SLIT. It is however 
unclear if this benefit is maintained over several years post-discontinuation of AIT or indeed whether 
AIT is a cost-effective intervention.   
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Figure 1: Conceptualization of systematic review of allergen immunotherapy for the prevention of 
allergic disease  
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Figure 2: PRISMA flow diagram  
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Figure 3: Random-effects meta-analysis of effectiveness of AIT in preventing short-term risk of 
developing first new allergic disease 
 
 
 
Nc=number in control group; Ni=number in intervention group; mode=route of administration of AIT 
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Figure 4: Random-effects meta-analysis of effectiveness of AIT in short-term prevention of 
asthma in those with allergic rhinitis 
 
 
 
 
Nc=number in control group; Ni=number in intervention group; mode=route of administration of AIT 
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Figure 5: Random-effects meta-analysis of effectiveness of AIT in long-term prevention of 
asthma in those with allergic rhinitis 
 
 
Nc=number in control group;vNi=number in intervention group;vmode=route of administration of AIT 
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Figure 6: Random-effects meta-analysis of effectiveness of AIT in short-term prevention of 
allergic sensitization 
 
 
Nc=number in control group; Ni=number in intervention group; mode=route of administration of AIT 
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Figure 7: Random-effects meta-analysis of effectiveness of AIT in long-term prevention of 
allergic sesnitization 
 
 
 
 Nc=number in control group; Ni=number in intervention group; mode=route of administration of AIT 
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Author/ 
year/ 
country 
Number of studies(N)/ 
subjects included(n)/age  
Participants: 
Disease status  
Specified primary 
outcome, and 
secondary 
outcomes of 
interest 
 
Comparators 
(intervention/controls)/ 
route of administration 
Type of allergy 
and allergens 
used for AIT 
Quality Main 
outcome/key 
findings 
Comment 
Primary outcome: Development of new allergic disease in previously healthy subjects or development of a second allergic disease in subjects already suffering from another allergic disease 
Crimi, 2004, 
Italy 
 
 
n=30 
15 randomized to receive 
injections of Parietaria pollen 
vaccine, 15 received placebo 
injections 
Age range: 20-54 yrs.  
 
 
Non-asthmatic 
subjects with 
seasonal rhinitis 
and 
monosensitized to 
Parietaria judaica. 
Effect on 
development of 
asthma and 
bronchial 
hyperresponsiveness. 
SCIT vs. placebo 
 
Rapid updosing cluster 
regimen for 7 weeks, 
followed by monthly 
injections for 34 months. 
Allergic rhinitis. 
 
Parietaria pollen. 
Medium A total of 9/29 
patients 
developed asthma 
symptoms at the 
end of the study: 
of these 7 (47%) 
were in the 
placebo group, 
2(14%) in the 
SCIT group 
(P=0.056). 
 
No changes seen in  
bronchial  
hyper- 
responsiveness 
to methacholine or 
sputum  
Authors conclude 
that Parietaria  
SCIT appears to  
prevent natural  
progression 
of allergic rhinitis 
to asthma  
suggesting 
that SCIT should  
be considered  
earlier in the  
management of   
AR, however  
the results were  
Table 1: Characteristics and main findings from RCTs 
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eosinophilia.  not statistically 
significant. 
Grembiale, 
2000, Italy 
 
 
n=44 
22 randomized to receive 
increasing doses of house dust 
mite allergen extract 
subcutaneously, 22 received 
placebo. 
Age range: 10-38 yrs. 
Subjects with a 
documented 
history of atopic 
rhinitis, no 
reported 
symptoms 
compatible with 
asthma. 
Effect on 
development of 
asthma and 
bronchial 
hyperresponsiveness. 
SCIT vs. placebo 
 
Increasing doses of 
allergen extract followed 
by monthly maintenance 
treatment. 
Allergic rhinitis. 
 
House dust mite. 
High None of the SCIT 
group developed 
asthma at the end 
of the 2-yrs 
treatment period 
compared to 9% 
in the placebo 
group (p=0.49). 
 
At end of study, 
methacholine 
PD20FEV1 was 
within normal 
range of 50% of 
treated subjects 
(p<0.0001) and it 
was significantly 
higher in 
intervention 
group compared 
to placebo group 
(p<0.0001). 
 
No changes in 
methacholine 
PD20FEV1 in 
All subjects had  
normal lung  
function test at  
inclusion and  
were well matched  
on methacholine  
responsiveness at  
the beginning of  
the study. 
 
All subjects  
underwent  
Methacholine 
challenge after  
1 yr and 2 yrs of  
treatment. 
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placebo group 
throughout the 
study. 
 
Positive  
correlation  
between  
methacholine  
PD20FEV1 before  
SCIT and  
magnitude of  
improvement in  
bronchial  
reactivity suggest  
that early  
intervention is  
likely to be of  
greater benefit. 
Holt, 2013, 
USA and 
Australia 
n=50 
25 randomized to receive 
mixture of soluble allergens 
given daily for 12 months, 25 
randomized to placebo. 
Children with 
positive atopic 
family history; a 
personal history of 
atopic dermatitis, 
and sensitization to 
one or more food 
Effect on 
development of 
asthma and 
sensitizations, safety. 
SLIT (drops) vs. placebo. 
 
12 months course of 
SLIT. Outcome 
assessment at 48 months. 
Atopic dermatitis. 
 
House dust mite, 
cat, timothy grass. 
Medium No difference in 
asthma 
prevalence 
between the two 
groups (4/25 in 
SLIT group; 4/25 
in placebo group) 
at 48 months. No 
Since there was  
no differences in 
antibody titers 
between active  
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Age range: 18-3 months, 
subsequently reduced to 12 
months. 
allergen. significant 
differences in 
rates of 
sensitization. 
and placebo  
group at the  
6-month  
sampling point, 
recruitment was 
terminated and 
the study status 
changed to 
pilot study. 
Jacobsen, 
2007, multi-
sited study 
(Europe) 
 
Niggemann, 
2006 
 
Möller, 2002 
 
 
n=205 at baseline, 103 
randomized to 3 yrs of 
subcutaneous SIT, 102 served 
as open control group.  
Age range at baseline: 6-14 yrs. 
 
Total follow up at 10 yrs: 
n=147 (79 from intervention 
group, 68 controls). 
Follow-up at 5 years (2 years 
after end of treatment): 183. 
Follow-up at 3 years (end of 
treatment): 191. 
Children with 
history of birch 
and/or grass 
pollen induced 
seasonal AR.  
Effect on 
development of 
asthma and 
bronchial 
hyperresponsiveness. 
SCIT vs. no intervention 
 
3-year course of SCIT 
after a 0-season. Up-
dosing performed with 
depot extracts with weekly 
injections over 15-20 
weeks or as rush 
immonutherapy with 
aqueous extracts. 
Maintenance injections 
every 6 weeks for 3 yrs. 
Allergic rhinitis. 
 
Grass, birch. 
Low Longitudinal 
treatment effect 
shows OR for no-
asthma 4.6 (95% 
CI; 1.5-13.7) in 
favour of SCIT 
group after 10 
years. 
 
At 5 yrs. follow-
up, SCIT-group 
had significantly 
less asthma 
compared to 
controls (OR 
2.68, 95% CI; 1.3-
Treatment effect 
 was adjusted for  
bronchial  
hyperresponsiveness and  
asthma status at  
baseline, and  
includes  
observations at  
3, 5 and 10 yrs  
follow-up. 
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 5.7).  
 
Result after 3 
years i.e. at end of 
treatment show 
significantly fewer 
asthma symptoms 
among actively 
treated children 
compared to 
controls (OR 
2.52, P<0.05). 
No significant 
differences 
between SCIT 
and control group 
in bronchial 
responsiveness to 
methacholine in 
change from 
baseline of PC20 
after 10 years. 
 
Authors conclude  
that findings from the 
10 yrs. follow up demonstrated the  
long-lasting benefit of SCIT in relation  
to prevention of asthma. 
 
 
 
Marogna, 
2008, Italy 
 
 
n=216 
144 randomized to SLIT, 72 
received drugs only. 
 
Age range: 5-17 yrs. 
Children with 
allergic rhinitis 
with/without 
intermittent 
asthma. 
Effect on 
development of 
asthma, new 
sensitizations and 
bronchial 
hyperreactivity.  
 
SLIT vs. 
pharmacotherapy. 
 
Build-up phase for 
approx.. 50 days 
followed by SLIT 3 
times a week in the 
maintenance phase. 
SLIT administered as 
AR, asthma. 
 
Mite, grass, birch, 
Parietaria.   
Low Higher 
occurence of 
intermittent and 
persistent asthma 
in control group 
(30/66, 45.4%) 
compared to the 
SLIT group 
(17/130, 13.1%).  
Patients were 
followed up 
for 3 yrs. 
 
Adherence to 
SLIT was 80% 
or higher in 
73.8% of 
patients. No 
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Safety. 
 
 
drops. 
98 for mites, 41 for 
grasses, 4 for birch, and 
1 for Parietaria  
 
 
 
Lower occurence 
of new 
sensitizations in 
SLIT group 
(4/130) than 
among controls 
(23/66) (OR 
0.06; 95% CI, 
0.02-0.17).  
Increased rate of 
polysensitizations 
in control group 
compared to 
SLIT group (OR 
SLIT vs. control 
at yr. 3: 0.33; 
95% CI, 0.17-
0.61). 
 
One patient 
reported 
systemic itching 
 
 
difference in 
dropout 
frequency 
between 
groups. 
 
Reduced onset 
of new 
sensitizations 
and 
intermittent or 
mild persistent 
asthma, and 
decreased 
bronchial 
hyperreactivity 
in children 3 
years after 
treatment. 
Möller, 
1986, 
Sweden 
 
 
n=30 
14 randomized to active 
capsules (birch pollen 
preparation), 16 to placebo.  
Age range: 8-16 yrs. 
Children with 
rhinoconjunctivitis. 
Effect on 
development of 
asthma and safety 
(part of aim of 
studying immune 
responses during 
OIT).  
Oral (capsules) vs. 
placebo. 
 
Treatment with capsules 
continued for 10 months. 
Rhinoconjunctivitis 
due to birch 
pollinosis. 
 
Birch. 
Medium No development 
of asthma in oral 
IT arm compared 
with 5 patients in 
the placebo arm. 
 
Similar  
side effects noted 
 (nausea,  
abdominal colic,  
diarrhea) in both  
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groups.  
No systemic  
reactions seen.   
Novembre, 
2004, Italy 
 
 
n=113 
54 randomized to SLIT group, 
59 randomized to standard 
symptomatic therapy. 
Age range: 5-14 yrs. 
Children with hay 
fever limited to 
grass pollen. 
Effect on 
development of 
asthma. 
SLIT (drops) vs. 
pharmacotherapy. 
 
A 3-year coseasonal 
protocol was used 
consisting of build-up 
and maintenance phases 
with an extract of mixed 
grass pollens. SLIT was 
administered for 4 
months a year.  
 
Hay fever due to 
grass pollen. 
 
Mixed grass 
pollens. 
Medium After first year of 
treatment, 6 of 
the SLIT patients 
had asthma 
compared to 6 in 
the control 
group. After the 
second year, 7 
SLIT patients 
and 16 controls 
had asthma 
(p=.058). After 
the third year, 8 
SLIT patients 
and 18 controls 
had asthma 
(P=.0412). 
 
Relative risk of 
development of 
asthma after 3 
years was 3.8 (95 
CI; 1.5-10.0) in 
control group 
compared to 
intervention 
group. 
 
At entry into 
the study, no 
subject 
reported 
seasonal 
asthma with 
more than 3 
episodes per 
season. 
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Song, 2014, 
China 
 
 
n=102 
51 randomized to SCIT, 51 to 
pharmacotherapy/symptomatic 
treatment only. 
 
Age: >5 yrs. 
Patients with AR 
allergic to house 
dust mites. 
Effect on onset of 
asthma and 
development of new 
sensitizations. 
SCIT vs. 
pharmacotherapy. 
 
SCIT for 3 yrs. with initial 
updosing followed by 
maintenance once every 6 
weeks for 3 yrs. 
AR, asthma. 
 
House dust mite. 
Low In the SCIT 
group no patients 
developed asthma 
and few new 
sensitizations 
occurred (2/43, 
[4.7%]).  
 
In the control 
group, 9/41 
(22%) developed 
asthma and 17/41 
(41.5%) new 
sensitizations.  
 
Differences were 
statistically 
significant 
(p<0.01). 
 
Follow-up 2 yrs. 
after  
discontinuation 
of SCIT.  
 
Authors conclude  
that early 
application 
of SCIT can  
prevent the  
development 
of asthma.  
 
 
Valovirta, 
multinational  
(11 
European 
countries) 
 
 
n=812 after seven 
months of screening  
 
Age range: 5-12 yrs. 
Patients with grass 
pollen-induced 
AR, without 
asthma, and no 
overlapping 
symptomatic 
allergies 
 
Time to onset of 
asthma 
SLIT vs. placebo once 
daily for 3 years, followed 
by a blinded observational 
period of 2 years. 
 
SQ-standardized grass 
Grass. High In SLIT group of 
398 patients 34 
developed asthma 
and in the control 
group of 414, 39 
developed asthma 
defined by strict 
diagnostic criteria 
including beta-2-
Not yet published 
but data 
available 
 at EudraCT 
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allergy 
immunotherapy tablet 
reversibilitest, no 
difference 
demonstrated 
between groups 
P=0.67.  At the 
end of the five 
year trial period 
the number of 
subjects with 
asthma symptoms 
or asthma 
medication usage 
in the SLIT group 
was less than in 
the placebo group 
(OR 0.66; P 0.036; 
95%CI 
[0.45;0.97]) 
Yamanaka, 
2015, Japan 
 
 
n=29 (27 due to withdrawal 
during the course of the study). 
13 were randomized to SLIT 
group, 14 to placebo group.  
 
Age range: 18-52 yrs. 
Asymptomatic 
subjects sensitized 
to Japanese cedar 
pollen. 
Effect on 
development of 
cedar pollinosis. 
SLIT vs. placebo.  
 
SLIT group received 
graded extracts of 
standardized Japanese 
cedar pollen followed by 
maintenance therapy.  
Sensitized to 
pollen. 
 
Japanese cedar 
pollen. 
Low No significant 
difference in 
development of 
symptoms of 
pollionosis 
between groups 
after first year of 
treatment (4 in 
SLIT/1 in 
placebo group). 
In the second 
year, 7 of the 
placebo group 
and none of the 
SLIT group 
developed 
Significant  
increase in IL-10  
producing 
T cells and B  
cells in SLIT  
group,  
Significant  
decrease in IL-10  
producing 
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symptoms.  
 
Ratio of 
development of 
pollinosis in the 
SLIT group was 
significantly lower 
than in the 
placebo group in 
the second year of 
the trial (p=.0098, 
Fisher's exact 
test). 
monocytes in  
placebo group. 
 
 
Zolkipli, 
2015, United 
Kingdom 
 
 
n=111 
57 assigned to house dust mite 
oral IT, 54 assigned to placebo. 
Age range: less than 1 yr. 
Infants at high risk 
of atopy (2 or 
more first-degree 
family members 
with allergic 
diseases (asthma, 
AR, eczema, or 
food allergy) but 
negative skin prick 
test responses to 
common allergens 
at randomization. 
Effect on 
development of 
eczema, wheeze, and 
food allergy; 
development of 
sensitizations and, 
and adverse 
events/safety. 
Oral AIT (drops) vs. 
placebo. 
 
House dust mite extract 
and placebo solution were 
administered orally twice 
daily for 12 months.  
High risk. 
 
House dust mite. 
High No effect on 
house dust mite 
sensitization, 
eczema, wheeze, 
and food allergy. 
Significant 
reduction (P=.03) 
in sensitization to 
any common 
allergen (16%; 
95% CI 1.7-
30.4%) in the 
active group 
(5[9.4%]) 
compared to the 
placebo group 
(13[25.5%]) after 
12 months of 
Children were  
assessed every 3  
months.  
 
Differences in  
morbidity and pet  
ownership across  
groups did not  
influence  
direction or size  
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treatment.  
 
Treatment was 
well tolerated 
with no 
differences in 
numbers or 
nature of adverse 
events between 
groups. 
 
of estimated  
differences in  
outcomes. 
 
. 
Secondary outcome: Development of new allergic sensitization(s) (or allergic immunresponse(s)) after end of intervention 
Dominicus, 
2012, 
Germany  
 
 
n=154 
77 patients were randomized to 
receive SCIT with grass pollen, 
77 were assigned to placebo 
group. 
 
Follow-up included 26 patients 
from ex-SCIT group and 13 
control patients.  
 
Age range:18-60 years. 
Adult patients 
allergic to grass 
pollen with 
rhinoconjunctivitis 
with or without 
asthma. 
Effect on 
development of new 
sensitizations. 
SCIT vs. placebo. 
 
Patients received weekly 
pre-seasonal subcutaneous 
immunotherapy with 
either grass pollen extract 
or placebo for 2 yrs. Both 
groups received active 
treatment in the third 
treatment yr.  
Grass pollen 
allergy. 
 
Grass pollen.  
Low Number of 
patients who did 
not develop new 
sensitizations 
during the 3 year's 
follow-up after 
cessation of SCIT 
was higher in Ex-
SCIT group (20 
patients, 77%) 
compared to 
control group (3 
patients, 23%). 
  
This prospective  
follow-up study  
ended 3 yrs after  
cessation of SCIT. 
 
Authors conclude 
that SCIT has  
long-term 
effects in reducing 
onset of new 
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sensitizations.  
García, 
2010, Spain 
 
 
n=56 
37 patients were randomized to 
the SLIT group, 17 were in the 
placebo group. 
 
Age range: 18-65 yrs. 
Peach-allergic 
patients. 
Effect on 
development of new 
sensitizations. 
SLIT vs. placebo. 
 
Treatment with 
standardized peach extract 
or placebo continued for 
6 months.  
    
Peach allergy. 
 
Peach. 
High A total of 3 
patients in the 
SLIT group 
developed 
clinically 
irrelevant 
sensitizations. No 
new sensitizations 
in the placebo 
group. 
 
New sensitizations 
were to single  
allergens and  
rated as of scarce  
magnitude and  
no clinical  
relevance. 
Limb, 2006, 
USA 
 
 
n=82 
41 were randomized to 
immunotherapy, 41 to placebo. 
 
Subjects were enrolled in 
childhood (age at inclusion 5-
12 yrs) and followed up in 
adulthood (age at follow-up 
17-31yrs). 
Children with 
moderate-to-severe 
asthma. 
Effect on 
development of new 
sensitizations 
SCIT vs. placebo. 
 
SCIT was given with a 
mixture of up to seven 
aeroallergen extracts and 
maintenance injections 
continued every 2 weeks 
for 24 months, and every 
3 weeks until debriefing. 
 
 
Asthma. 
 
Broad-spectrum 
aeroallergens. 
Medium Similar acquisition 
of new skin test 
sensitivities from 
time of 
randomization 
into original 
childhood trial to 
debriefing (15 vs. 
20%; p=0.28) and 
to adult follow-up 
(30 vs. 31%; 
p=0.75) among 
both SCIT and 
placebo group. 
 
23/41 (56%) in 
the SCIT group 
vs. 31/41 (76%) 
The 82 evaluated 
patients did not  
differ from the  
remaining 39  
patients from  
the original trial  
with regard to  
age,ethnicity,  
gender,  
number of  
positive 
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in the placebo 
group acquired 
one or more new 
sensitivity 
between 
randomization 
and debriefing 
(p=0.19). 
 
From debriefing 
to adult follow-
up, 38/40 (95%) 
in the SCIT group 
vs. 33/39 (85%) 
in the placebo 
group acquired at 
least one more 
new sensitivity. 
 
skin tests or  
treatment- 
designated 
allergens at  
randomization,  
or total 
serum IgE  
(all p-values >0.1). 
  
Long-term  
evaluation of  
broad- 
spectrum IT  
(mean follow 
-up 10.8  
yrs). 
 
Types of new  
ensitivities  
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were similar 
between 
treatment and  
placebo groups.  
Marogna, 
2004, Italy 
 
 
n=511 
319 patients were randomized 
to SLIT, 192 patients to 
control group. 
 
Mean age SLIT group = 22.8 
yrs 
 
Mean age control group = 21.5 
yrs. 
Patients with 
allergic rhinitis 
with/without 
intermittent 
asthma. 
Effect on 
development of new 
sensitizations, 
safety/adverse 
events. 
SLIT vs. 
pharmacotherapy. 
 
Patients were evaluated in 
an observation period of 1 
yr, followed by SLIT 
prescribed for relevant 
allergens in a build-up and 
maintenance phase for 
approximately 3 yrs. 
AR, asthma. 
 
Mites, grass, birch, 
parietaria, 
mugworth. 
Low Significantly 
lower incidence 
of new 
sensitizations in 
SLIT group 
(16/271 [5.9%]) 
compared to 
pharmacotherapy 
group (64/170 
[38%]) at the end 
of the 3-yrs. 
treatment period 
(p < 0.0001). 
 
Four of 271 
patients (1.5%) 
reported one 
episode of 
generalized 
itching within 30 
min. of taking the 
dose, all appeared 
in maintenance 
phase and self-
resolved without 
therapy in <2 
Adherence to  
SLIT measured 
 by volume of  
remaining  
extract. 
 
During the 3yrs  
of study,70  
patients  
dropped out: 
48 (15%) in  
SLIT 
 group, 22  
(12%) 
 in control  
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hours. Five 
dropouts in SLIT 
group due to 
adverse events 
(oral itching, 
asthma, 
abdominal pain). 
 
group. 
 
 No significant  
overall  
difference  
between 
the two groups.    
Pifferi, 
2002, Italy 
 
 
n=29 
15 patients were randomized 
to SCIT group, 14 to control 
group. 
 
Age range: 6-14 yrs. 
Children with 
asthma and 
monosensitizedto 
house dust mite. 
Effect on 
development of new 
sensitizations, 
bronchial 
hyperreactivity and 
safety. 
SCIT vs. 
Pharmacotherapy (?) 
 
After a 1-yr. run-in 
period, SCIT were 
administered through 
gradually increasing doses 
until maximum tolerated 
dose. 
 
SCIT continued for 3 yrs. 
Asthma, AR. 
 
House dust mite. 
Medium SCIT group 
showed 
significant 
decrease in non-
specific bronchial 
hyperreactivity. 
The ratio of 
incidence of 
“non-
improvement” in 
bronchial 
reactivity in the 
SCIT group 
compared to 
controls was 0.3; 
95%CI 0.11-
0.87). 
 
No new 
sensitivity 
occured in SCIT 
group whilst 
All SCIT 
patients 
reached the 
suggested dose 
for 
maintenance 
phase. 
 
Four dropouts 
in control 
group. 
 
Treatment and 
control groups 
were matched 
for age, 
asthma 
severity, 
respiratory 
function and 
bronchial 
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5/10 in the 
control group 
developed new 
sensitizations 
(P=0.01). 
 
No major local 
or systemic side-
effects reported 
during the study. 
hyperreactivity. 
Szépfalusi, 
2015, 
Austria 
 
 
n=31 
15 randomized to SLIT group 
with either grass pollen or 
house dust mite extract 
according to the individual 
sensitization profile), 16 
randomized to placebo group. 
 
Age range: 2-5 yrs. 
Healthy persons 
with allergic 
sensitizations but 
no clinical disease.  
 
Effect on 
development of new 
sensitizations. 
 
Safety. 
SLIT vs. placebo. 
 
 
After dose-up phase, 
therapy continued for 2 
yrs. 
 
 
Sensitization to 
pollen and/or 
mites. 
 
House dust mite, 
grass. 
High Preventive 
application of 
SLIT in young 
children was safe 
(no relevant side 
effects in 21.170 
single 
applications).  
 
No difference in 
rate of new 
sensitizations in 
SLIT group 
compared to 
placebo group 
after 12 and 24 
months of 
treatment. 
Verum-treated 
patients had a 
significant up-
regulation of 
Children were  
mono/ 
oligoclonally  
sensitized,  
clinically  
asymptomatic. 
 
 
Rate of new  
Sensitizations 
increased  
significantly over 
time in both 
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allergen-specific 
IgG (p<0.05) and 
IL10-dependent 
inhibition was 
observed in vitro 
in treatment 
group but not in 
placebo group. 
 groups. 
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Author/ 
year/ 
country 
Number of 
studies(N)/ 
subjects 
included(n)
/age 
Participants: 
Disease status 
Specified primary 
outcome, and 
secondary 
outcomes of 
interest 
 
Comparators 
(intervention/controls)
/ 
route of 
administration 
Type of allergy 
and allergens 
used for AIT 
Quality Main 
outcome/key 
findings 
Comment 
Primary outcome:Development of new allergic disease in previously healthy subjects or development of a second allergic disease in subjects already suffering from another allergic disease 
Schmitt, 
2015, 
Germany 
 
 
n=118,754 
stratified 
into one 
group 
exposed to 
AIT in 2006 
(n=2,431) or 
an 
unexposed 
group 
(n=116,323) 
 
All ages 
included. 
Patients with AR but 
without comorbid 
asthma. 
 
AR at least two ICD-
10 codes for AR. 
Effect on onset of 
asthma. 
AIT stratified as SCIT, 
SLIT drops, SLIT 
tablets, and 
combinations. 
Asthma. 
 
All types of 
allergens used 
for AIT 
included. 
Low Risk of incident 
asthma was 
significantly lower 
in patients exposed 
to AIT (RR, 
0.60;95% CI, 0.42-
0.84) compared to 
patients not 
exposed to AIT in 
2006. 
 
Sensitivity analyses 
found significant 
preventive effects 
of SCIT (RR, 0.57; 
95% CI, 0.38-0.84) 
and AIT including 
native allergens 
(RR, 0.22; 95% CI, 
0.02-0.68) but no 
statistical 
Consecutiv
e cohort of 
patients 
based on 
routine 
health care 
data from 
German 
National 
Health 
Insurance 
beneficiarie
s.  
 
Exposed 
and 
unexposed 
groups 
were 
observed 
for incident 
Table 2: Characteristics and main findings from CBAs 
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significance for 
SLIT drops, or 
combinations of 
SCIT and SLIT.  
 
AIT for 3 yrs. 
tended to have 
stronger 
preventive effects 
than AIT for a 
shorter duration 
(RR, 0.62; 95% CI, 
0.39-0.98 vs. 0.57; 
95% CI, 0.34-
0.94).  
 
No effect 
modification by 
age and sex was 
observed.  
asthma 
from 2007-
12. 
 
Authors 
conclude 
that AIT 
effectively 
prevents 
asthma in 
patients 
with AR in 
a real-world 
setting. 
Secondary outcome: Development of new allergic sensitization(s) (or allergic immunresponse(s)) after end of intervention 
Asero, 2004, 
Italy 
 
 
n=691  
284 patients 
received SCIT as 
part of routine 
outpatient care, 
407 not 
undertaking SCIT 
served as controls. 
Age range: >12 
years 
Patients 
monosensitized to 
airborne allergens 
(grass, pellitory, 
ragweed, birch or 
house dust mite) 
first seen between 
Jan 1st 1989-Dec 
31st 1998 and 
reevaluated no less 
than 2 years after 
the first visit/after 
Effect on 
development of 
new sensitizations 
SCIT/pharmacotherapy. 
 
SCIT was administered 
following a perennial 
schedule. Patients 
enrolled in SCIT 
treatment according to 
own choice. 
 
Sensitization to 
pollen. 
 
Grass, pellitory, 
birch, ragweed, 
house dust mite. 
Low Significantly higher 
prevalence of new 
sensitizations to 
ragweed and/or 
birch pollen in 
subjects receiving 
SCIT (132/284; 
46%) than among 
controls (95/407; 
23%) (p<0.001). 
No preventive 
effect  against  
denovo  
sensitizations to  
birch and  
ragweed pollen 
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the end of SCIT.  Weekly doses given 
during build-up phase 
followed by maintenance 
doses.  
 
Denovo 
sensitizations to 
other airborne 
allergens (besides 
ragweed and birch 
pollen) were rare 
and did not show 
any difference 
between SCIT and 
control groups.  
 
 
in adult  
monosensitized  
patients. 
 
 
 
Des Roches, 
1997, France 
 
 
n=44 
22 patients 
received SCIT, 22 
age-matched 
patients served as 
controls. 
Age range: 2-6 yrs. 
Children with 
asthma and 
monosensitizedto 
house dust mite.  
Effect on 
development of 
new sensitizations 
SCIT vs. 
pharmacotherapy.  
 
Rush immunotherapy 
and maintenance 
injections using a 
standardized 
Dermatophagoides 
pteronyssinus extract. 
 
Follow-up on an annual 
basis for 3 yrs. 
Asthmatic 
children 
sensitized to 
house dust mites. 
 
Dermatophagoid
es pteronyssinus. 
Low Ten of 22 children 
in SCIT group 
(45%) did not 
develop new 
sensitizations 
compared to none 
of the 22 children 
in the control 
group. Occurence 
of new 
sensitizations was 
thus significantly 
less in SCIT group 
compared to 
controls (p<0.001). 
 
The findings 
suggest that  
SCIT in  
asthmatic 
children  
monosensitized  
to house dust  
mites alters the 
natural course of allergy by  
preventing the  
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development of  
new  
sensitizations. 
Di Rienzo, 
2003, Italy 
 
 
n=60  
35 accepted 
treatment with 
SLIT, 
25 received only 
medication. 
 
Age range: 3-17, 
mean age 8.5 yrs. 
Children with AR 
and/or mild to 
moderate asthma 
due to house dust 
mites.  
Effect on 
development of 
new sensitizations.  
SLIT vs. 
pharmacotherapy. 
 
SLIT was administered 
continuously for 4-5 
yrs. according to 
guidelines. 
 
AR with/without 
asthma. 28 children 
were 
monosensitized to 
mites alone, the 
remaining patients 
had concomitant 
sensitizations. 
 
House dust mite. 
Low No significant 
difference in onset 
of new 
sensitizations in the 
two groups. 
 
Only 3/35 patients 
in SLIT group and 
2/25 patients in 
control group 
developed new 
sensitizations 
during the 10 yrs. 
period. 
Patients were  
evaluated at  
baseline, end of  
SLIT and 4-5  
yrs. after SLIT  
discontinuation. 
   
Eng, 2006, 
Switzerland 
 
  
 
 
n=28 included in 
the original study 
and self-assigned to 
receive either SCIT 
(n=14) or 
standardized 
pharmacotherapy 
(n=14) for 3 yrs.. 
 
At 6 yrs. follow-up 
after 
Children with a 
history of severe 
grass pollen AR 
for at least 2 yrs. 
with/without 
asthma but with 
immunoglobulin 
(Ig)E-mediated 
sensitivity to 
seasonal allergens 
only (grass pollen 
with/without tree 
Effect on 
development of 
new sensitizations. 
SCIT vs. 
pharmacotherapy. 
 
Grass pollen SCIT was 
administered 
preseasonally for 3 
years. 
AR, asthma. 
 
Grass. 
Low Six yrs. after 
discontinuation of 
SCIT, a 
significantly lower 
number of SCIT 
patients had 
developed new 
sensitizations 
(8/13) compared to 
controls (10/10) 
(p<0.02). 
The two study  
groups were  
matched for  
gender, 
age, prevalence  
of seasonal  
asthma, and  
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discontinuation of 
SCIT, 13 SCIT 
patients and 10 
controls were 
included. 
 
At 12 yrs. of 
follow-up, 12 SCIT 
patients and 10 
controls were 
included. 
 
Age range at 
inclusion: 5-16 yrs. 
 
pollen).  
There was a 
significantly lower 
occurence of new 
sensitizations in 
SCIT group 
compared to 
controls at 12-yrs 
follow-up (58% vs. 
100%; p<0.05). 
 
wheal size at  
study enrollment.  
 
This prospective 
follow-up study  
finds a  
reduction in  
onset of new  
sensitizations 6  
yrs after  
discontinuation  
of SCIT.  
The reduction 
 is sustained at  
12 yrs. of  
follow-up. 
Gulen, 2007, 
Turkey 
 
 
n=129 patients. 
70 patients 
accepted SCIT, 59 
were treated with 
Children with 
asthma 
monosensitized to 
house dust mite. 
Effect on 
development of 
new sensitizations. 
SCIT vs. 
pharmacotherapy.  
 
SCIT was administered 
Asthma. 
 
House dust mite. 
Low At the end of the 6-
yrs. study period, a 
total of 41 (33%) of 
patients had 
developed new 
The study found 
no association  
between family 
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medication only. 
 
Age range: 6-10 
yrs. 
for four yrs. sensitizations.  
 
Significantly higher 
prevalence of new 
sensitizations in 
SCIT group (31/68; 
45.5%) compared 
to controls (10/55; 
18.1%) (OR 3.77, 
95% CI, 1.52-9.5, 
p=0.001). 
 
 
history of atopy  
and development  
of new allergic  
sensitizations. 
Harmanci, 
2010, 
Turkey 
 
 
n=122 patients. 
62 patients 
accepted SCIT, 
remaining 60 
patients were 
treated with 
medication only. 
 
Age range: 8-18 
yrs. 
Children with 
intermittent 
asthma 
with/without AR, 
monosensitized to 
house dust mite. 
Effect on 
development of 
new sensitizations. 
SCIT vs. 
pharmacotherapy. 
 
SCIT was administered 
for four yrs. 
Asthmawith/witho
ut AR. 
 
House dust mite. 
Low No significant 
difference in 
development of 
new sensitizations 
after the 4-yrs. 
study period. A 
total of 36/53 
(67.9%) patients in 
SCIT group had no 
new sensitizations 
compared to 38/52 
(73.0%) in control 
group (P=0.141). 
Authors conclude  
that SCIT may  
not prevent 
onset of new  
sensitizations in  
asthmatic  
children who are  
monosensitized 
to house dust 
mites. 
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Inal, 2007, 
Turkey 
 
 
n=147 
45 patients 
underwent SCIT 
with absorbed 
extracts, 40 
patients underwent 
SCIT with aqueous 
extracts, 62 
patients were 
controls receiving 
only 
pharmacologic 
treatment.  
 
Age range: 6-16 
yrs. 
Children with 
rhinitis and/or 
asthma 
monosensitized to 
house dust mite. 
Effect on 
development of 
new sensitizations. 
SCIT vs. 
pharmacotherapy. 
 
SCIT treatment 
continued for 5 yrs. 
Follow-up at end of 
treatment. 
 
SCIT group was 
subdivided into 
absorbed extracts and 
aqueous extracts 
because the latter was 
used more commonly 
than absorbed extracts 
at the beginning of the 
study. 
AR/asthma. 
 
House dust mite. 
Low  At 5 year follow-up, 
a total of 64/85 
(75.3%) in the 
SCIT group 
showed no new 
sensitizations 
compared to 29/62 
children (46.7%) in 
the control group 
(P=.002). 
SCIT was  
recommended 
to all patients. 
Those who  
rejected SCIT  
were included as 
controls. 
 
Children  
developing new  
sensitizations  
had higher atopy  
scores compared 
to those who did 
not develop new 
sensitizations. 
The same  
pattern was  
observed in the  
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SCIT group  
but this was not  
statistically  
significant. 
 
Marogna, 
2010, Italy 
 
 
n=78 
57 in SLIT group 
subdivided into 
different length of 
SLIT (3 yrs: 19; 4 
yrs: 21; 5 yrs:17) 
21 patients in 
control group. 
 
Adult patients 
(mean age of 22.2 
+/- 5.2 yrs. at 
inclusion). 
Patients with 
allergic rhinitis 
with/without 
asthma lasting for 
at least 2 yrs and 
monosensitized to 
house dust mites. 
Effect on 
development of 
new sensitizations 
and bronchial 
hyperreactivity. 
 
Safety. 
SLIT for 3, 4 or 5 yrs. 
vs. pharmacotherapy. 
 
Build-up phase for 
approx.. 50 days 
followed by SLIT 3 
times a week in the 
maintenance phase. 
 
AR, asthma, 
sensitized to house 
dust mites. 
 
House dust mite. 
Low New sensitizations 
occurred in all 
control subjects 
over 15 yrs.  
 
Among the SLIT 
group, 3/14 
(21.4%) in the 
SLIT3 group, 2/16 
(12.5%) in the 
SLIT4 group, and 
2/17 (11.7%) in the 
SLIT5 group 
developed new 
sensitizations. 
 
Difference in  
occurence of new  
sensitizations 
The study-design 
was prospective,  
open, controlled, 
4-parallel-group, 
partially 
randomized. If  
patients refused  
SLIT,they were  
assigned to the  
control group. 
 
 
Assignment to  
groups was  
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across SLIT and  
control group 
became significant 
at year 6 (P=.03). 
 
5 patients had 
transient oral 
itching during 
build-up phase, 2 
patients reported 1 
episode of 
generalized itching 
on maintenance. All 
adverse events 
occurred 30 min. 
after dosing and 
spontaneously 
disappeared. 
 
 
made yearly. 
 
Length of follow 
-up was 15 yrs. 
 
All dropouts  
were due to  
protocol  
deviations.  
 
Adherence to  
SLIT greater  
than 80%  
measured 
by volume of  
extract in  
returned vials.  
  
 
Ohashia, n=159 Patients Effect on IT (unknown route) Monosensitized to  Unclear Four years after Patients 
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2009, Japan  
 
 
80 in mite 
immunotherapy 
group, 27 in house 
dust mite IT 
group, 52 in 
pharmacotherapy 
group. 
Age: >20 yrs. 
 
 
monosensitized to 
house dust mites. 
 
 
development of 
new sensitizations 
for 4 yrs using a) D. 
farinae extracts (mite 
immunotherapy 
group) or b) house 
dust mite mixtures vs. 
pharmacotherapy. 
 
 
 
mites. 
 
House dust mite. 
enrollment, the 
incidence of new 
sensitizations to 
pollen was 28.0% 
in the 
pharmacotherapy 
group, 6.3% in the 
mite IT group, and 
22.2% in the house 
dust mite IT 
group.  
 
Significantly lower 
incidence of new 
sensitizations in 
mite IT group 
compared to 
control group 
(p=0.0008), but no 
significant 
differences 
between HD IT 
group and controls 
(p=0.5999). 
 
were 
divided 
into groups 
according 
to their 
own 
choice.  
 
 
Ohashib, 
2009, Japan 
 
 
n=176, 194 in 
pollen 
immunotherapy 
group, 72 in 
pharmacotherapy 
group. 
Age: adult. 
Patients 
monosensitized 
to Japanese cedar 
pollen. 
Effect on 
development of 
new sensitizations 
IT (unknown route) 
for 4 yrs. vs. 
pharmacotherapy 
Monosensitized to 
Japanese cedar 
pollen. 
 
Japanese cedar 
pollen. 
 
 
Unclear After four years of 
follow-up, there 
were no significant 
differences in new 
sensitizations (to 
other types of 
pollen) between 
groups. 
Patients 
were 
divided into 
groups 
according to 
their own 
choice.  
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 Authors 
conclude 
that new 
sensitization
s in allergic 
patients can 
be inhibited 
by mite 
immunother
apy but not 
by 
immunother
apy using 
other kinds 
of allergen 
extracts.  
Pajno, 
2001, Italy 
 
 
n=134 enrolled 
75 patients in SCIT 
group, 63 children 
in control group 
according to own 
choice. 
 
Age range: 5-8 yrs. 
Children with 
intermittent 
asthma 
with/without 
rhinitis 
monosensitized 
to house dust 
mite. 
Effect on 
development of 
new sensitizations. 
SCIT vs. 
pharmcotherapy. 
 
SCIT with mite mix 
was administered 
during the first three 
years in the 
intervention group. 
After induction 
phase, maintenance 
dose was 
administered once a 
month for 3 years. 
AR, asthma. 
 
House dust mite. 
Low At the end of the 
6-year study 
period, 52/69 
(75.4%) patients in 
the SCIT group 
showed no new 
sensitizations 
compared to 
18/54 (33.3%) in 
the control group 
(p<0.0002). 
 
Authors conclude 
that SCIT may 
prevent onset of 
new sensitizations 
in children with 
respiratory 
Allocation 
to treatment 
vs. control 
arm 
dependent 
upon 
parent's 
willingness 
to accept 
SCIT.  
 
All patients 
had 
intermittent 
asthma at 
enrolment. 
 
All patient’s 
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symptoms 
monosensitized to 
house dust mite.  
 
parents 
were 
instructed 
to decrease 
exposure to 
mites (e.g. 
by frequent 
vacuuming, 
washing 
sheets at 
least once a 
week, 
removal of 
plants/soft 
toys from 
bedroom). 
 
Both groups 
were 
followed for 
a total of 6 
yrs. 
Purello-
D'Ambrosi
o, 2001, 
Italy 
 
 
n=8396  
Group A included 
7182 patients given 
SCIT for 4 yrs. 
Followed by drugs 
for at least 3 yrs. 
Group B included 
1214 patients 
treated only with 
drugs for at least 7 
yrs. 
Patients with 
allergic rhinitis 
and/or asthma 
monosensitized 
to respiratory 
allergens.  
Effect on 
development of 
new sensitizations 
SCIT vs. 
pharmacotherapy. 
 
Patients in group A 
underwent SCIT with 
relevant allergens for 
4 yrs. with an 
induction phase 
followed by 
maintenance 
injections at 4-week 
Asthma, AR, 
monosensitization. 
 
Parietaria, grass, 
olea, Compositae 
(mix), Corylaceae-
Betulaceae (mix), 
mites.  
Low Significantly lower 
risk of new 
sensitizations in 
SCIT group 
(1706/7182, 
[23.75%]) 
compared to 
controls 
(826/1214, 
[68.03%]) after 4 
yrs. of treatment.  
 
Effect of 
SCIT 
observed 
retrospectiv
ely. 
 
SCIT was 
proposed to 
all patients. 
Those who 
accepted 
were 
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Age range: >13 yrs 
old. 
intervals. 
 
 
Three yrs. later, 
1936/7182 
(26.95%) among 
SCIT group and 
932/1214 
(76.77%) in 
control group had 
developed new 
sensitizations. 
Both comparisons 
were highly 
significant 
(p<0.0001). 
 
Asthmatic 
patients, treated 
with SIT or not, 
were more prone 
to develop 
polysensitization 
compared to 
patients with 
rhinitis only. 
allocated 
into group 
A. 
 
Both groups 
were 
divided into 
subgroups 
according to 
presence of 
asthmatic 
symptoms 
at 
enrolment. 
 
All patients 
were 
followed-up 
as 
outpatients 
in the 
period 
1980-99. 
 
Authors 
conclude 
that specific 
immunother
apy reduced 
new 
sensitization
s in 
monosensiti
zed subjects 
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suffering 
from 
respiratory 
allergic 
diseases. 
Reha, 2007, 
Turkey 
 
 
n=107 
56 patients in the 
SCIT group, 51 
patients in the 
control group. 
 
Age range: 7-12 
yrs. 
Children with 
intermittent 
asthma sensitized 
to house dust 
mite or pollen 
species. 
Effect on 
development of 
new sensitizations. 
SCIT vs. 
pharmacotherapy. 
 
 
 
 
Asthma, AR, 
monosensitization 
to grass pollen 
species or house 
dust mites. 
 
House dust mite, 
grass. 
Low At 5 years follow-
up, 35/43 
(81.39%) of 
patients in house 
dust mite IT 
group and 10/13 
(76.92%) patients 
in grass pollen IT 
group showed no 
new sensitizations. 
In the control 
group, 20/51 
(53.84%) had 
developed new 
sensitizations. 
Difference 
between SIT 
groups and 
control group was 
statistically 
significant 
(p=0.033). 
 
SCIT and 
control 
group were 
matched for 
age, asthma 
and/or AR 
severity, and 
respiratory 
function. 
 
Authors 
conclude 
that SCIT 
appears to 
prevent 
developmen
t of new 
sensitization
s. 
Tella, 2003, 
Spain 
 
n=100  
66 were treated 
with SCIT, 34 
received 
Patients with AR 
and/or asthma 
monosensitized. 
Effect on 
development of 
new sensitizations. 
SCIT vs. 
pharmacotherapy. 
 
Duration of treatment 
AR, asthma, 
monosensitization 
to grass pollen, 
Parietaria judaica 
pollen or 
Dermatophagoides 
Low No statistically 
significant 
differences in risk 
of developing new 
sensitizations 
between SCIT 
Comparisons  
were made  
between 
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 medication only. 
 
Age range: 6-69 
yrs.  
was at least 3 yrs. spp. 
 
Grass pollen, 
Parietaria judaica, 
Dermatophagoides 
pteronyssinus, 
Dermatophagoides 
farinae. 
 
 
 
 
group and controls 
(RR=0.97, 95% CI, 
0.72-1.3). A total 
of 24/66 (36.4%) 
patients in the 
SCIT group had 
new sensitizations 
compared to 
13/34 (38.2%) 
among controls.  
baseline and  
after 3-5 yrs.  
of SCIT.  
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Table 3: Quality assessment of RCTs 
Author, year Design Adequate 
sequence 
generation 
Allocation 
concealment 
 
Blinding 
patients/perso
nnel 
Blinding of 
outcome 
assessors 
Incomplete 
outcome data 
addressed 
Free of 
selecting 
reporting 
 
Free of 
other 
bias* 
Overall quality 
assessment 
Crimi, 2004 RCT Yes Yes Yes Yes No Yes No Medium 
Dominicus, 
2012 
RCT Unclear Yes Yes No Unclear No No Low 
Garcia, 2010 RCT Yes Yes Yes Yes Yes Yes Yes High 
Grembiale, 
2000 
RCT Yes Yes Yes Yes Yes Yes Yes High 
Holt, 2013 RCT Unclear Yes Yes Yes Yes Yes Yes Medium 
Jacobsen, 
2007 
RCT Yes Yes  No No No Yes No Low 
Limb, 2006 RCT Yes Yes Yes Yes No Yes No Medium 
Marogna, 
2004 
RCT Yes No No No Yes Yes No Low 
Marogna, 
2008 
RCT Unclear No No No Yes Yes No Low 
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Möller, 1986 RCT Unclear Yes Yes Yes No Yes No Medium 
Novembre, 
2004 
RCT Yes No No No Yes Yes No Medium 
Pifferi, 2002 RCT Unclear Unclear Unclear Yes No Yes Yes Medium 
Song, 2014 RCT Yes No Unclear Unclear No Yes Yes Low 
Szepfalusi, 
2014 
RCT Yes Yes Yes Yes Yes Yes Yes High 
Valovirta, 
2016 
RCT Yes Yes Yes Yes Yes Yes Yes High 
Yamanaka, 
2014 
RCT No Unclear Unclear Unclear Yes Yes Yes Low 
Zolkipli,   
2015 
RCT Yes Yes Yes Yes Yes Yes Yes High 
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Table 4: Quality assessment of CBAs 
 
Author, 
year 
Design Adequate 
sequence 
generation 
Allocation 
concealment 
 
Blinding 
patients/pers
onnel 
Blinding of 
outcome 
assessors 
Incomplete 
outcome data 
addressed 
Free of 
selecting 
reporting 
 
Free of 
other 
bias* 
Overall quality 
assessment 
Asero, 2004 CBA No No No No Yes Yes No Low 
Des Roches 
1997 
CBA No No No No Yes Yes No Low 
Di Rienzo, 
2003 
CBA No No No No Yes Yes No Low 
Eng 2006 CBA No No No No Yes Yes No Low 
Gulen, 2007 CBA No No No No Yes Yes No Low 
Harmanci, 
2010 
CBA No No No No Yes Yes No Low 
Inal, 2007 CBA No No No No Yes Yes No Low 
Marogna, 
2010 
CBA No No No No Yes Yes No Low 
Ohashi, 2009 CBA Unclear Unclear Unclear Unclear Unclear Unclear Unclear Low 
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Ohashi, 2009 CBA Unclear Unclear Unclear Unclear Unclear Unclear Unclear Low 
Pajno, 2001 CBA No No No No Yes Yes No Low 
Purello 
D’Ambrosia,  
2001 
CBA No No No No Yes Yes No Low 
Reha, 2007 CBA Unclear Unclear Unclear Unclear Yes Yes No Low 
Schmitt, 
2015 
CBA No No No No Yes Yes No Low 
Tella, 2003 CBA No No No No Yes Yes No Low 
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Table 5: List of excluded studies with reasons for exclusion 
 
Reference Incorrect 
study 
design 
Incorrect 
outcome 
Incorrect 
intervention 
Other 
Antúnez C, Mayorga C, Corzo JL, Jurado A, Torres 
MJ. Two year follow-up of immunological response in 
mite-allergic children treated with sublingual 
immunotherapy. Comparison with subcutaneous 
administration. Pediatr Allergy Immunol 2008; 
19:210-8. 
 X   
Bachert C. Sublingual immunotherapy. A survey on 
the basis of controlled studies on efficacy, tolerability, 
long-term effects and prevention in children and 
adults with ALK-Scherax preparations. [German]. 
Allergologie 2007;30:1-13. 
X    
Baron-Bodo V, Zimmer A, Bouley J, Bonvalet M, 
Moussu H, Wambre E, Ricarte C, Horiot S, Kwok 
WW, Horak F, Beaumont O, Nony E, Mascarell L, 
Moingeon P. Clinical efficacy of allergen-specific 
sublingual immunotherapy correlates with the 
induction of tolerogenic dendritic cell, but not CD4+ 
regulatory T cell, markers. Allergy 2013; 68:20. 
 X   
Blumberga G, Groes L, Dahl R. SQ-standardized 
house dust mite immunotherapy as an 
immunomodulatory treatment in patients with 
asthma. Allergy 2011; 66:178-85. 
 X   
Bousquet J. Sublingual immunotherapy: from proven 
prevention to putative rapid relief of allergic 
symptoms. Allergy 2005; 60:1-3. 
X    
Bucher X, Pichler WJ, Dahinden CA, Helbling A. 
Effect of tree pollen specific, subcutaneous 
immunotherapy on the oral allergy syndrome to apple 
and hazelnut. Allergy 2004; 59:1272-6. 
 X   
Cantani A, Micera M. Significant decrease of IgE 
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Appendix 1: Search strategy 
 
Search strategy 1 
(MEDLINE, EMBASE) 
 
1. exp Primary prevention/ 
2. Primary prevention.mp. 
3. exp Secondary prevention/ 
4. Secondary prevention.mp. 
5. exp Tertiary prevention/ 
6. Tertiary prevention.mp. 
7. Prevention.mp. 
8. Etiology.mp. 
9. Epidemiologic*.mp. 
10. (“risk of developing” or “risk for development”).mp. 
11. (effect* or cause* or protect* or risk*).mp. 
12. or/1-11 
13. exp Desensitization, Immunologic/ 
14. exp Immunotherapy/ 
15. Desensitization.mp.  
16. Hyposensitisation.mp. 
17. Allergy vaccination.mp. 
18. (Immunotherapy or allergen immunotherapy).mp. 
19. Subcutaneous immunotherapy.mp. 
20. Epicutaneous immunotherapy.mp. 
21. Intradermal immunotherapy.mp. 
22. Sublingual immunotherapy.mp. 
23. Oral Immunotherapy.mp. 
24. Oral desensitization.mp. 
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25. Specific oral tolerance induction.mp. 
26. Oral tolerance induction.mp. 
27. Intranasal immunotherapy.mp. 
28. Bronchial immunotherapy.mp. 
29. Intralymphatic immunotherapy.mp.  
30. Specific immunotherapy.mp. 
31. Or/13-30 
32. exp Intervention Studies/ 
33. Intervention studies.mp. 
34. exp Clinical Trial/ 
35. trial.mp. 
36. Clinical trial.mp. 
37. exp Controlled Clinical Trial/ 
38. Controlled Clinical Trial.mp. 
39. Randomized Controlled Trial.mp. 
40. Quasi-randomized trial.mp. 
41. Non-randomized trial.mp. 
42. exp Placebos/ 
43. Placebos.mp. 
44. exp Random allocation.mp. 
45. Random allocation.mp. 
46. exp Double-blind method/ 
47. Double-blind method.mp. 
48. Double-blind design.mp. 
49. exp single-blind method/ 
50. Single-blind method.mp. 
51. Single-blind design.mp. 
52. Triple-blind method.mp. 
53. Random*.mp. 
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54. (Controlled before and after stud*).mp. 
55. Interrupted Time Series Analysis/ or interrupted time series.mp. 
56. Search:.tw. 
57. Review.pt. 
58. Systematic review.tw. 
59. Meta analysis.mp,pt. 
60. Case series.mp. 
61. (Case$ and series).tw. 
62. Cost:.mp. 
63. Cost effective:.mp. 
64. Cost utility:.mp. 
65. Exp Health care Costs/ 
66. (Costs and Costs Analysis).mp. 
67. Economic evaluation*.mp. 
68. ((cost effective* adj1 analys*) or cost minimi?ation analys* or cost benefit analys* or cost utility 
analys* or cost consequence analys* or finances).mp. 
69. Or/32-68 
70. 12 and 31 and 69 
 
Search strategy 2 
(Cochrane library, HTA, EED, CINAHL, ISI Web of Science, TRIP) 
 
(Prevention or “primary prevention” or secondary prevention” or “tertiary prevention” or etiology or 
“risk of developing” or “risk for development” or effect* or cause* or protect* or risk) 
 
AND  
(Immunologic, desensiti* or hyposensitization or immunotherapy or allergen immunotherapy or specific 
immunotherapy or allergen specific immunotherapy or allergy vaccination or subcutaneous 
immunotherapy or epicutaneous immunotherapy or intradermal immunotherapy or sublingual 
immunotherapy or oral immunotherapy or oral desensitization or specific oral tolerance induction or oral 
tolerance induction or intranasal immunotherapy or bronchial immunotherapy or intralymphatic 
immunotherapy) 
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AND 
(Intervention stud* or experimental stud* or trial or clinical trial* or controlled clinical trial or randomi* 
controlled trial or random allocation or single blind method or double blind method or triple blind 
method or random* or systematic review or meta-analysis or case series or economic evaluation* or cost 
effective* analys* or cost minimization analys* or cost benefit analys* or cost utility analys* or cost 
consequence analys* or finances) 
 
Appendix 2: Experts consulted 
 
1. Lars Jacobsen, Denmark 
2. Eva Maria Varga, Austria 
3. Erkka Valovirta, Finland 
4. Peter Eng, Switzerland 
5. Ojedo, Pedro, Spain 
 
Appendix 3: PRISMA Checklist 
 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration 
number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4-5 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design 
(PICOS).  
5 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including 
registration number.  
5, 8 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
5-6 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched.  
6, 61-63 
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Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
61-63 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
5-7 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators.  
5-7 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
5-7 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis.  
6-7 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis.  
7-8 
 
  
Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).  
7-8 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified.  
7-8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
8, 31 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations.  
8-21, 37-
56 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
8-21, 58-
59 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
8-21, 37-
56 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
11-14, 16-
17, 19, 32-
36 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  11-13, 16-
17, 19, 32-
36 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 16]).  
11-14, 16-
17, 19, 32-
36  
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each 
main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
21-22 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval of identified research, reporting bias).  
21 
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Conclusions  26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research.  
22 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
23 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
 
 
 
 
